150 related articles for article (PubMed ID: 8387218)
1. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
[TBL] [Abstract][Full Text] [Related]
2. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
Rathbun RC; Martin ES
Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
[TBL] [Abstract][Full Text] [Related]
3. Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
Nelson MR; Moyle GJ; Gazzard BG
Clin Infect Dis; 1993 Feb; 16 Suppl 1():S59-62. PubMed ID: 8093848
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
[TBL] [Abstract][Full Text] [Related]
5. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
Cooley TP; Kunches LM; Saunders CA; Perkins CJ; Kelley SL; McLaren C; McCaffrey RP; Liebman HA
Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
[TBL] [Abstract][Full Text] [Related]
6. Didanosine: long-term follow-up of patients in a phase 1 study.
Lambert JS; Seidlin M; Valentine FT; Reichman RC; Dolin R
Clin Infect Dis; 1993 Feb; 16 Suppl 1():S40-5. PubMed ID: 8093846
[TBL] [Abstract][Full Text] [Related]
7. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.
Valentine FT; Seidlin M; Hochster H; Laverty M
Rev Infect Dis; 1990; 12 Suppl 5():S534-9. PubMed ID: 1974725
[TBL] [Abstract][Full Text] [Related]
9. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
[TBL] [Abstract][Full Text] [Related]
10. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG
Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724
[TBL] [Abstract][Full Text] [Related]
11. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Spruance SL; Pavia AT; Peterson D; Berry A; Pollard R; Patterson TF; Frank I; Remick SC; Thompson M; MacArthur RD; Morey GE; Ramirez-Ronda CH; Bernstein BM; Sweet DE; Crane L; Peterson EA; Pachucki CT; Green SL; Brand J; Rios A; Dunkle LM; Cross A; Brown MJ; Ingraham P; Gugliotti R; Schindzielorz AH; Smaldone L
Ann Intern Med; 1994 Mar; 120(5):360-8. PubMed ID: 7905722
[TBL] [Abstract][Full Text] [Related]
12. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients.
Rozencweig M; McLaren C; Beltangady M; Ritter J; Canetta R; Schacter L; Kelley S; Nicaise C; Smaldone L; Dunkle L
Rev Infect Dis; 1990; 12 Suppl 5():S570-5. PubMed ID: 2166965
[TBL] [Abstract][Full Text] [Related]
13. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.
Dolin R; Lambert JS; Morse GD; Reichman RC; Plank CS; Reid J; Knupp C; McLaren C; Pettinelli C
Rev Infect Dis; 1990; 12 Suppl 5():S540-9; discussion S549-51. PubMed ID: 1974726
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
Vella S; Floridia M; Dally LG; Tomino C; Fragola V; Weimer LE; Milazzo F; Mazzotta F; Moroni M; Pastore G; Scalise G; Sinicco A; Ortona L; De Rienzo B; Dianzani F
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):462-9. PubMed ID: 8757422
[TBL] [Abstract][Full Text] [Related]
15. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
Cooley TP; Kunches LM; Saunders CA; Ritter JK; Perkins CJ; McLaren C; McCaffrey RP; Liebman HA
N Engl J Med; 1990 May; 322(19):1340-5. PubMed ID: 2139174
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
[TBL] [Abstract][Full Text] [Related]
17. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
Skowron G; Bozzette SA; Lim L; Pettinelli CB; Schaumburg HH; Arezzo J; Fischl MA; Powderly WG; Gocke DJ; Richman DD; Pottage JC; Antoniskis D; McKinley GF; Hyslop NE; Ray G; Simon G; Reed N; LoFaro ML; Uttamchandani RB; Gelb LD; Sperber SJ; Murphy RL; Leedom JM; Grieco MH; Zachary J; Hirsch MS; Spector SA; Bigley J; Soo W; Merigan TC
Ann Intern Med; 1993 Mar; 118(5):321-30. PubMed ID: 8094279
[TBL] [Abstract][Full Text] [Related]
18. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
Yarchoan R; Lietzau JA; Nguyen BY; Brawley OW; Pluda JM; Saville MW; Wyvill KM; Steinberg SM; Agbaria R; Mitsuya H
J Infect Dis; 1994 Jan; 169(1):9-17. PubMed ID: 7903976
[TBL] [Abstract][Full Text] [Related]
19. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
Yarchoan R; Pluda JM; Thomas RV; Mitsuya H; Brouwers P; Wyvill KM; Hartman N; Johns DG; Broder S
Lancet; 1990 Sep; 336(8714):526-9. PubMed ID: 1975038
[TBL] [Abstract][Full Text] [Related]
20. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
d'Arminio Monforte A; Musicco M; Galli M; Paga C; La Regina A; Lazzarin A; Angarano G; Milazzo F; Gritti F; Arlotti M; Mazzotta F; Visco G; Aiuti F; Moroni M
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):135-42. PubMed ID: 9105840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
